We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Centene Unveils Its 2025 Guidance, Reaffirms 2024 Outlook
Read MoreHide Full Article
Centene Corporation (CNC - Free Report) recently revealed its 2025 outlook at its investor day, reaffirming its 2024 guidance.The company continues to expect premium and service revenues within $143.5-$144.5 billion, up from the 2023 figure of $140.1 billion.
Adjusted earnings per share (EPS) is projected to be at least $6.80, suggesting a significant improvement from the 2023 reported figure of $6.68. The Zacks Consensus Estimate for the same is currently pegged at $6.83 per share. The company also reiterated its HBR guidance in the band of 88.3-88.5%.
2025 Outlook
Centene expects total revenues within $166.5-$169.5 billion, higher than the 2024 expected figure of $159-$161 billion. The company estimates premium and service revenues to be in the $154-$156 billion range, higher than the 2024 guided range. Factors contributing to year-over-year growth include rate increases, expansion into new markets for Medicaid, continued growth in individual health insurance, rising number of uninsured individuals for Marketplace and dual expansions, and improvements in Star ratings for Medicare business.
Centene's 2025 adjusted EPS is projected to exceed $7.25, indicating growth from the 2024 estimate of at least $6.80 per share. This underscores positive operational momentum. The 2025 adjusted EPS guidance surpasses the Zacks Consensus Estimate of $7.01 per share. It continues to expect adjusted profit to achieve an average annual growth of 12-15% over the long term.
Centene expects the health benefits ratio to be within 88.4-89% in 2025. The company also estimates the adjusted SG&A expense ratio to be in the 8.1-8.7% range. It projects the adjusted effective tax rate between 22% and 23%.
Diluted shares outstanding for 2025 are expected to be 491-494 million. It anticipates to repurchase shares worth $2 billion in late 2025. CNC also expects to achieve its long-term revenue growth CAGR of 7-8%. Medicaid is expected to grow 6-7%, Marketplace in the mid to high single digits, and Medicare in the high single digits to 10% in the long term.
CNC’s Price Performance
Centene’s shares have plunged 24.3% in the year-to-date period compared with the industry’s 11.4% decline.
The Zacks Consensus Estimate for Pediatrix Medical’s current-year earnings indicates 7.1% year-over-year growth. MD beat earnings estimates in three of the trailing four quarters and met once, with an average surprise of 9.9%. The consensus mark for its current-year revenues is pegged at $2 billion.
The Zacks Consensus Estimate for CareDx’s current-year earnings indicates a 167.2% year-over-year improvement. CDNA beat earnings estimates in each of the trailing four quarters, with an average surprise of 135.2%. The consensus mark for revenues implies 17.5% growth from the year-ago period.
The Zacks Consensus Estimate for Encompass Health’s 2024 earnings implies a 17.6% increase from the year-ago reported figure. EHC beat earnings estimates in each of the trailing four quarters, with an average surprise of 13.6%. The consensus mark for its current-year revenues is pegged at $5.34 billion, which indicates an 11.2% year-over-year increase.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Shutterstock
Centene Unveils Its 2025 Guidance, Reaffirms 2024 Outlook
Centene Corporation (CNC - Free Report) recently revealed its 2025 outlook at its investor day, reaffirming its 2024 guidance.The company continues to expect premium and service revenues within $143.5-$144.5 billion, up from the 2023 figure of $140.1 billion.
Adjusted earnings per share (EPS) is projected to be at least $6.80, suggesting a significant improvement from the 2023 reported figure of $6.68. The Zacks Consensus Estimate for the same is currently pegged at $6.83 per share. The company also reiterated its HBR guidance in the band of 88.3-88.5%.
2025 Outlook
Centene expects total revenues within $166.5-$169.5 billion, higher than the 2024 expected figure of $159-$161 billion. The company estimates premium and service revenues to be in the $154-$156 billion range, higher than the 2024 guided range. Factors contributing to year-over-year growth include rate increases, expansion into new markets for Medicaid, continued growth in individual health insurance, rising number of uninsured individuals for Marketplace and dual expansions, and improvements in Star ratings for Medicare business.
Centene's 2025 adjusted EPS is projected to exceed $7.25, indicating growth from the 2024 estimate of at least $6.80 per share. This underscores positive operational momentum. The 2025 adjusted EPS guidance surpasses the Zacks Consensus Estimate of $7.01 per share. It continues to expect adjusted profit to achieve an average annual growth of 12-15% over the long term.
Centene expects the health benefits ratio to be within 88.4-89% in 2025. The company also estimates the adjusted SG&A expense ratio to be in the 8.1-8.7% range. It projects the adjusted effective tax rate between 22% and 23%.
Diluted shares outstanding for 2025 are expected to be 491-494 million. It anticipates to repurchase shares worth $2 billion in late 2025. CNC also expects to achieve its long-term revenue growth CAGR of 7-8%. Medicaid is expected to grow 6-7%, Marketplace in the mid to high single digits, and Medicare in the high single digits to 10% in the long term.
CNC’s Price Performance
Centene’s shares have plunged 24.3% in the year-to-date period compared with the industry’s 11.4% decline.
Image Source: Zacks Investment Research
CNC's Zacks Rank & Key Picks
Centene currently carries a Zacks Rank #3 (Hold).
Some better-ranked and promising stocks in the broader Medical sector are Pediatrix Medical Group, Inc. (MD - Free Report) , CareDx, Inc. (CDNA - Free Report) and Encompass Health Corporation (EHC - Free Report) . Each stock presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Pediatrix Medical’s current-year earnings indicates 7.1% year-over-year growth. MD beat earnings estimates in three of the trailing four quarters and met once, with an average surprise of 9.9%. The consensus mark for its current-year revenues is pegged at $2 billion.
The Zacks Consensus Estimate for CareDx’s current-year earnings indicates a 167.2% year-over-year improvement. CDNA beat earnings estimates in each of the trailing four quarters, with an average surprise of 135.2%. The consensus mark for revenues implies 17.5% growth from the year-ago period.
The Zacks Consensus Estimate for Encompass Health’s 2024 earnings implies a 17.6% increase from the year-ago reported figure. EHC beat earnings estimates in each of the trailing four quarters, with an average surprise of 13.6%. The consensus mark for its current-year revenues is pegged at $5.34 billion, which indicates an 11.2% year-over-year increase.